No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 3, 2012, Pages 229-235

  Gandhi, Rajesh T ^a   Coombs, Robert W ^b,c   Chan, Ellen S ^d   Bosch, Ronald J ^d   Zheng, Lu ^d   Margolis, David M ^e   Read, Sarah ^f   Kallungal, Beatrice ^g   Chang, Ming ^b   Goecker, Erin A ^b   Wiegand, Ann ^h   Kearney, Mary ^h   Jacobson, Jeffrey M ⁱ   D'Aquila, Richard ^j   Lederman, Michael M ^k   Mellors, John W ^l   Eron, Joseph J ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Virology Division ^*  (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^j VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

2 LTR circles; HIV 1; HIV 1 DNA; Raltegravir; Reservoirs; T cell activation; Viral replication

Indexed keywords

RALTEGRAVIR; VIRUS DNA; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; POLYMERASE CHAIN REACTION; PYRROLIDINONES; RNA, VIRAL; T-LYMPHOCYTES; VIREMIA; VIRUS REPLICATION;

EID: 84859752894     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823fd1f2     Document Type: Article

References (20)

1. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282: 1627-1632. (Pubitemid 29513968)
2. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3: e46.
3. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105: 3879-3884. (Pubitemid 351723493)
4. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS. 2011;25: 885-897.
5. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science. 2009;323: 1304-1307.
6. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187: 1534-1543. (Pubitemid 36578959)
7. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7: e1000321.
8. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16: 460-465.
9. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50: 912-919.
10. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010; 24: 2451-2460.
11. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011;203: 960-968.
12. Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis. 2004;189: 1452-1465. (Pubitemid 38543595)
13. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 2000;6: 76-81. (Pubitemid 30048530)
14. Pierson TC, Kieffer TL, Ruff CT, et al. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol. 2002;76: 4138-4144. (Pubitemid 34250581)
15. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010;202: 1553-1561.
16. Brussel A, Mathez D, Broche-Pierre S, et al. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS. 2003;17: 645-652. (Pubitemid 36521070)
17. Cone RW, Hobson AC, Huang ML. Coamplified positive control detects inhibition of polymerase chain reactions. J Clin Microbiol. 1992;30: 3185-3189.
18. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007;196: 1500-1508. (Pubitemid 351411987)
19. Besson GJ, McMahon D, Maldarelli F, et al. Short-course raltegravir intensification does not increase 2-LTR episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis. [published online ahead of print October 19, 2011] doi: 10.1093/cid/cir721.
20. Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011;477: 95-98.